Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER ADULTS TRANS IN THE UK BIOBANK COMMUNITY COHORT

    Authors: Janice L Atkins; Jane AH Masoli; Joao Delgado; Luke C Pilling; Chia-Ling C Kuo; George Kuchel; David Melzer

    doi:10.1101/2020.05.06.20092700 Date: 2020-05-08 Source: medRxiv

    Background: Older COVID-19 hospitalized patients frequently have hypertension HP hypertension MESHD, diabetes MESHD or coronary heart disease MESHD ( CHD MESHD), but whether these are more common than in the population is unclear. During the initial epidemic in England, virus testing for older adults TRANS was restricted to symptomatic hospitalized patients. We aimed to estimate associations between pre-existing diagnoses and COVID-19 status, in a large community cohort. Methods: UK Biobank (England) participants assessed 2006 to 2010, followed in hospital discharge records to 2017. Demographic and pre-existing common diagnoses association tested with COVID-19 status (16th March to 14th April 2020) in logistic models, adjusted for demographics, study site and other diagnoses. Results: There were 274,356 participants aged TRANS 65+, including 448 (0.16%) hospitalized COVID-19 patients. Common co-morbidities in patients were hypertension HP hypertension MESHD (58.5%), coronary heart disease MESHD ( CHD MESHD, 21.1%), history of fall HP or fragility fractures MESHD (30.6%), and type 2 diabetes MESHD (19.6%). However, in adjusted models, COVID-19 patients were more likely than other participants to have pre-existing dementia HP dementia MESHD (OR=3.07 95% CI 1.71 to 5.50), COPD MESHD (OR= 1.82 CI 1.33 to 2.49), depression MESHD (OR=1.81 CI 1.36 to 2.40), type 2 diabetes MESHD (OR=1.70 CI 1.30 to 2.21), chronic kidney disease HP chronic kidney disease MESHD and atrial fibrillation HP atrial fibrillation MESHD. Hypertension HP Hypertension MESHD was modestly associated (OR=1.29 CI 1.04 to 1.59), but CHD MESHD (OR=0.92 CI 0.71 to 1.20) prevalence SERO was similar in COVID-19 patients and other participants. Conclusion: Specific co-morbidities are disproportionally common in older adults TRANS who develop severe COVID-19. Tailored interventions may be needed, as these results do not support simple age TRANS-based targeting to prevent severe COVID-19 infection MESHD.

    Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy

    Authors: Paolo Giorgi Rossi; Massimiliano Marino; Debora Formisano; Francesco Venturelli; Massimo Vicentini; Roberto Grilli; - The Reggio Emilia COVID-19 Working Group

    doi:10.1101/2020.04.13.20063545 Date: 2020-04-16 Source: medRxiv

    Objectives. To describe the age TRANS- and sex-specific prevalence SERO of SARS-CoV-2 disease MESHD (COVID-19) and its prognostic factors. Design. Population-based prospective cohort study on archive data. Setting. Preventive services and hospital care in the province of Reggio Emilia, Northern Italy. Participants. All 2653 symptomatic patients who tested positive for SARS-CoV-2 from February 27 to April 2, 2020 in the province of Reggio Emilia. Main outcome measures. Hospitalization and death up to April 2, 2020. Results. Females TRANS had higher prevalence SERO of infection MESHD than males TRANS below age TRANS 50 (2.61 vs. 1.84 per 1000), but lower in older ages TRANS (16.49 vs. 20.86 per 1000 over age TRANS 80). Case fatality rate reached 20.7% (22/106) in cases with more than 4 weeks follow up. After adjusting for age TRANS and comorbidities, men had a higher risk of hospitalization (hazard ratio (HR) 1.4 95% confidence interval (95% CI) 1.2 to 1.6) and of death (HR 1.6, 95% CI 1.2 to 2.1). Patients over age TRANS 80 compared to < age TRANS 50 had HR 7.1 (95% CI 5.4 to 9.3) and HR 27.8 (95% CI 12.5 to 61.7) for hospitalization and death MESHD, respectively. Immigrants had a higher risk of hospitalization (HR 1.3, 95% CI 0.99 to 1.81) than Italians and a similar risk of death MESHD. Risk of hospitalization and of death MESHD were higher in patients with heart failure MESHD (HR 1.6, 95% CI 1.2 to 2.1and HR 2.3, 95% CI 1.6 to 3.2, respectively), arrhythmia HP arrhythmia MESHD (HR 1.5, 95% CI 1.2 to 1.9 and HR 1.8, 95% CI 1.3 to 2.5, respectively), dementia HP dementia MESHD (HR 1.2, 95% CI 0.9 to 1.8 and HR 1.8, 95% CI 1.1 to 2.8, respectively), ischemic MESHD heart disease MESHD (HR 1.3, 95% CI 1.0 to 1.7 and HR 1.7, 95% CI 1.2 to 2.5, respectively), diabetes MESHD (HR 1.5, 95% CI 1.3 to 1.9 and HR 1.6, 95% CI 1.1 to 2.2, respectively), and hypertensions HP hypertensions MESHD(HR 1.4, 95% CI 1.2 to 2.6 and HR 1.6, 95% CI 1.2 to 2.1, respectively), while COPD increased the risk of hospitalization (HR 1.9, 95% CI 1.4 to 2.5) but not of death MESHD (HR 1.1, 95% CI 0.7 to 1.7). Previous use of ACE inhibitors has no effect on risk of death (HR 0.97, 95% CI 0.69 to 1.34) Conclusions. The mechanisms underlying these associations are mostly unknown. A deeper understanding of the causal chain from infection MESHD, disease onset, and immune response to outcomes may explain how these prognostic factors act.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.